Publications by authors named "Cayla G Skaggs"
Raloxifene (RAL) is an FDA-approved drug used to treat osteoporosis in postmenopausal women. RAL suppresses bone loss primarily through its role as a selective estrogen receptor modulator (SERM). This hormonal estrogen therapy promotes unintended side effects, such as hot flashes and increased thrombosis risk, and prevents the drug from being used in some patient populations at-risk for fracture, including children with bone disorders.
View Article and Find Full Text PDFArticle Synopsis
- - Patients with implantable cardioverter defibrillators (ICDs) benefit from remote monitoring, which allows quicker responses to heart rhythm events; however, they currently don’t have access to their own ICD data.
- - A study explored delivering ICD data to patients via a personal health record (PHR) to enhance their engagement and understanding of their heart health, using interviews with 21 patients over three months.
- - Key findings showed that patients want reassuring, clear, and relevant information about their ICD data; effective sharing of this information requires context and customization to meet individual needs.